Surfactant Disorders and Chronic Lung Disease
APSE
Surfactant Disorders Associated With Chronic Lung Disease in Children.
1 other identifier
observational
58
1 country
1
Brief Summary
Interstitial lung diseases (ILD) in children represent a heterogeneous group of rare and not well defined disorders. Genetic abnormalities of surfactant proteins B (SFTPB) and more recently C (SFTPC) have been shown to be related to these pathologies. However, variability in the lung disease phenotype suggests the involvement of other surfactant-associated genes such as ABCA3 (ATP-binding cassette, sub-family A, member, 3). Thus, the aim of this project is: 1) to assess the prevalence of SFTPC mutation in children with chronic lung diseases, 2) to precise clinical and radiological features of children with SFTPC mutation, and 3) to identify environmental or genetic factors that may explain the extreme variability of this disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2009
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 31, 2008
CompletedFirst Posted
Study publicly available on registry
November 3, 2008
CompletedStudy Start
First participant enrolled
September 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2012
CompletedNovember 19, 2012
November 1, 2012
2.8 years
October 31, 2008
November 16, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To assess the prevalence of SFTPC mutation in children with chronic lung diseases
At the inclusion visit
Secondary Outcomes (2)
To precise clinical and radiological features of children with SFTPC mutation
At the inclusion visit
To identify environmental or genetic factors that may explain the extreme variability of this disease
At the inclusion visit
Study Arms (1)
1
Children with chronic lung disease
Interventions
2 ml of whole blood for children 5 ml of whole blood for parents that will be used only if 1 mutation is found in children
Eligibility Criteria
French pulmonary units participating to the study
You may qualify if:
- Children from 1 month to 17 years old with radiological alveola-interstitial syndrome and:
- Oxygen weaning failure \> 1 month in term newborn babies(\>37th week of PCA)or\> 40 weeks of PCA in preterm babies
- Chronic respiratory disease define by chronic hypoxia and/or clinical signs of respiratory distress (cough, retractions, crackle)
You may not qualify if:
- informed consent denied
- absence of social security
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hopital Trousseau
Paris, 75012, France
Related Publications (3)
Epaud R, Delestrain C, Louha M, Simon S, Fanen P, Tazi A. Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations. Eur Respir J. 2014 Feb;43(2):638-41. doi: 10.1183/09031936.00145213. Epub 2013 Oct 17. No abstract available.
PMID: 24136335DERIVEDDelestrain C, Flamein F, Jonard L, Couderc R, Guillot L, Fanen P, Epaud R. [Lung diseases in children associated with inherited disorders of surfactant metabolism]. Rev Pneumol Clin. 2013 Aug;69(4):183-9. doi: 10.1016/j.pneumo.2013.05.002. Epub 2013 Jul 12. French.
PMID: 23856024DERIVEDFlamein F, Riffault L, Muselet-Charlier C, Pernelle J, Feldmann D, Jonard L, Durand-Schneider AM, Coulomb A, Maurice M, Nogee LM, Inagaki N, Amselem S, Dubus JC, Rigourd V, Bremont F, Marguet C, Brouard J, de Blic J, Clement A, Epaud R, Guillot L. Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children. Hum Mol Genet. 2012 Feb 15;21(4):765-75. doi: 10.1093/hmg/ddr508. Epub 2011 Nov 7.
PMID: 22068586DERIVED
Biospecimen
Whole blood, plasma, DNA
Study Officials
- PRINCIPAL INVESTIGATOR
Ralph Epaud, MD
Hopital Trousseau, APHP
Study Design
- Study Type
- observational
- Observational Model
- FAMILY BASED
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 31, 2008
First Posted
November 3, 2008
Study Start
September 1, 2009
Primary Completion
June 1, 2012
Study Completion
June 1, 2012
Last Updated
November 19, 2012
Record last verified: 2012-11